| 1 |
Dirican E, Akkiprik M, Ozer A (2016). Mutation distributions and clinical correlations of PIK3CA gene mutations in breast cancer. Tumour Biol. [Epub ahead of print]
|
| 2 |
Dirican E, Kaya Z, Gullu G, et al (2014). Detection of PIK3CA gene mutations with HRM analysis and association with IGFBP-5 expression levels in breast cancer. Asian Pac J Cancer Prev, 15, 9327-33.
DOI
|
| 3 |
Gallia GL, Rand V, Siu IM, et al (2006) PIK3CA gene mutations in pediatric and adult glioblastoma multiforme. Mol Cancer Res, 4, 709-14
DOI
|
| 4 |
Juarez Olguin H, Flores Perez J, Lares Asseff I, Loredo Abdala A, Carbajal Rodriguez L (2004). Comparative pharmacokinetics of acetyl salicylic acid and its metabolites in children suffering from autoimmune diseases. Biopharm Drug Dispos, 25, 1-7.
DOI
|
| 5 |
Klarenbeek S, van Miltenburg MH, Jonkers J (2013). Genetically engineered mouse models of PI3K signaling in breast cancer. Mol Oncol, 7, 146-64
DOI
|
| 6 |
Turturro SB, Najor MS, Ruby CE, Cobleigh MA, Abukhdeir AM (2016). Mutations in PIK3CA sensitize breast cancer cells to physiologic levels of aspirin. Breast Cancer Res Treat, 156, 33-43.
DOI
|
| 7 |
Whitman M, Kaplan DR, Schaffhausen B, Cantley L, Roberts TM (1985). Association of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation. Nature, 315, 239-42
DOI
|
webmaster
